MTVA: Phase 1 Part 3 16-Week Titration Study of DA-1726 to Initiate in April 2026…

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Phase 1 Part 3 Trial of DA-1726 to Initiate in April 2026 On March 18 ...
Monthly Prescribing Reference

Study Shows Modified Donanemab Titration Regimen Cuts Risk of ARIA-E

Modified titration was associated with a 41% lower relative risk of ARIA-E than the standard dosing regimen. Topline results were announced from a phase 3b trial evaluating various dosing regimens of ...

MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2025, and ...

New algorithm can better manage type 2 diabetes, study finds

A University of Virginia Center for Diabetes Technology-developed algorithm—paired with a continuous glucose monitor—can help ...
ascopubs.org

Patients with metastatic renal cell carcinoma who have benefit from axitinib dose titration: Analysis from a randomized, double-blind, axitinib dose titration phase II study.

Single-nucleotide polymorphisms (SNPs) associated with outcomes in patients with localized and metastatic renal cell carcinoma (RCC). This is an ASCO Meeting Abstract from the 2017 Genitourinary ...